Dr. Andrew L. Lux, Ph.D., is Chief Operating Officer, Vice President of AtriCure, Inc., since January 16, 2012. Since 2010, Dr. Lux served as the Senior Vice President of Manufacturing and Operations for IntriMed Technologies, a startup business focused on contract manufacturing of implantable medical devices. From 2008 to 2010, Dr. Lux was the Vice President of Research and Development, Operations and Service for WaterHealth International, Inc., a business focused on the water purification/disinfections markets. From 2006 to 2008, Dr. Lux was the General Manager for Medtronic, Inc.?s spinal division in Warsaw, Indiana, where he was responsible for the United States based manufacturing organization providing spinal implant and orthopedic instrumentation products. Prior to 2006, Dr. Lux served in a variety of executive capacities for medical device organizations including Baxter Healthcare, Inc., Medtronic, Inc., Johnson & Johnson and General Electric Company.
COO and VP
Age: 59 COO Since 2012 Ph.D
The company has return on total asset (ROA) of (10.22) % which means that it has lost $10.22 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (53.59) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 8.44 M in liabilities with Debt to Equity (D/E) ratio of 0.67 which is about average as compared to similar companies. AtriCure Inc has Current Ratio of 2.29 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Entity SummaryAtriCure, Inc., a medical device company, develops, manufactures, and sells cardiac surgical ablation systems designed to create precise lesions or scars in cardiac tissue. AtriCure Inc [ATRC] is traded on NASDAQ General Markets in USA. It is located in AtriCure, Inc.West Chester, OH and employs 230 people. Filter other
|Click to run this filter|| |
Filter Other Insiders
| ATRC Nasdaq
AtriCure Inc has less than 3.0 (%) percent chance of experiencing financial distress in the next 2 years of operations.
AtriCure price boundaries
Promote AtriCure and Andrew Lux